Global Remicade Biosimilars Market Overview
Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of 9.30% to extend a value of USD 34.4 Billion by 2034
Biosimilars refers to biological product that are highly similar or identical to already existing FDA approved drug for medication purpose. Remicade (infliximab) is a monoclonal antibody used in the treatment of Crohn’s disease in both adult and pediatric patients. It is also used for treatment of active ulcerative colitis, moderate to severe rheumatoid arthritis in combination with another drug.
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Global Remicade Biosimilars Market Dynamics
|
Drivers |
Restrains |
|
Rising incidence of autoimmune diseases, rheumatoid arthritis |
Side effects such as tuberculosis |
|
Accessibility to patients |
Stringent regulatory guidelines for development |
|
Faster reaction rate |
|
|
Investment in R & D of biosimilars |
|
Regional Insights:
On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
- North America market is estimated to witness a significantly high revenue share over the forecast period due to rising investment and funding.
- Systemic and faster drug review process.
- Stringent Regulatory Environment
- Streamlined manufacturing guidelines
- Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.
- Rising Health Awareness
- Rising government support
- Major investment for Research and Development
Global Remicade Biosimilars Market Segmentation
Dividing this target market into segments:
Remicade biosimilars market is segmented based on Disease Indication, and Region.
Regional Insights:
Disease Indication Insight
On the basis of Disease Indication, the target market is segmented into Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others
Report scope:
|
Attribute |
Details |
|
Market Size 2024 |
US$ 15.3 Billion |
|
Projected Market Size 2034 |
US$ 34.4 Billion |
|
CAGR Growth Rate |
9.30% |
|
Base year for estimation |
2023 |
|
Forecast period |
2024 – 2034 |
|
Market representation |
Revenue in USD Million & CAGR from 2024 to 2034 |
|
Market Segmentation |
By Disease Indication - Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.
Global Remicade Biosimilars Market Key Players
The key players operating the Remicade biosimilars market includes Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, and Napp Pharmaceuticals.
Global Remicade Biosimilars Market Key Issues Addressed
Recent Development:
The New Launched Product News,
- In August 2020, South Korea's Celltrion teamed up with U.K.-based drug delivery firm Intract Pharma to codevelop the world's first tablet version of infliximab, a biosimilar of Johnson & Johnson's immunology blockbuster Remicade. With intravenous and subcutaneous versions of the drug already under its belt, Celltrion hopes the tie-up will further secure its position in the Crohn's disease and ulcerative colitis fields.
- In December 2019, Avsola (infliximab-axxq), the fourth Remicade Biosimilar was approved by FDA. It is a tumor necrosis factor blocker intended for patients with rheumatoid arthritis, in combination with methotrexate, as well as for patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
Global Remicade Biosimilars Market Company Profile
- Janssen Biotech, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Alvogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Celltrion
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Nippon Kayaku
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Napp Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global Remicade Biosimilars Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysish
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
Market Segmentation, By Type, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Ulcerative Colitis
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Rheumatoid Arthritis
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Ankylosing Spondylitis
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- GCC
- Israel
- South Africa
- Rest of Middle East
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Janssen Biotech, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Alvogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Celltrion
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Nippon Kayaku
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Napp Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
Segments present in the remicade biosimilars market are by disease indication and by region.
Key players operating in the market of Remicade biosimilarinclude Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, and Napp Pharmaceuticals.
On the basis of disease indication, the Remicade biosimilar has been segmented ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, crohn’s disease, psoriatic arthritis, and plaque psoriasis.
Major investments for research and development of biosimilar production are expected to drive growth of the market
Various pharmaceutical manufactures developed biosimilar to Remicade, which lowered the market share of Remicade due to its high cost and fostered the market of Remicade biosimilars.